Navigation Links
Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution
Date:12/9/2009

SANTA MONICA, Calif. and WALTHAM, Mass., Dec. 10 /PRNewswire/ -- Reprints Desk, Inc., and QUOSA, Inc., today announced that Cubist Pharmaceuticals has become the first shared customer to activate integration between Reprints Desk's STM Document Delivery service with QUOSA's Virtual Library, which facilitates copyright-compliant article archiving and scientific literature re-use. The integrated solution features integration with Rightsphere, the rights advisory and management tool from Copyright Clearance Center (CCC), which already integrates independently with both Reprints Desk and QUOSA.

"The integration of QUOSA's powerful solution for archiving and sharing scientific journal articles with Reprints Desk's ultra-rapid document delivery service was a logical collaboration for delivering the efficiency and compliance benefits we've been seeking to enhance our eLiterature services," said A. Amyas Huston, Senior Manager of Medical Communications at Cubist. "With QUOSA already deployed and Reprints Desk delivery not requiring any platform fees or any IT information technology involvement from Cubist, the implementation within our workflow processes was fast and seamless."

Lexington MA-based Cubist Pharmaceuticals has been a QUOSA customer and a Reprints Desk customer since 2007. QUOSA serves a large and rapidly growing subscriber-base at leading pharmaceutical, biotechnology and other life-science companies, with solutions for efficiently managing and monitoring scientific literature. Reprints Desk earned the top ranking overall and in every category in the 2008 Document Delivery Best Practices and Vendor Scorecard by analyst and advisory firm Outsell, Inc., and scored a 97% customer satisfaction rating in Dun & Bradstreet's 2009 Open Ratings survey of existing Reprints Desk customers.


'/>"/>
SOURCE Reprints Desk, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lees Pharmaceuticals
2. BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors
3. ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
4. Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis
5. Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals Universal Flu Vaccine
8. Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference
9. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
10. Jazz Pharmaceuticals Appoints Kathryn Falberg as Chief Financial Officer
11. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets has announced the ... Film Industry Report 2014" report to their offering. ... Global And Chinese Medical X-Ray Film Industry Report 2014 ... state of the Global medical X-ray film industry with ... provides a basic overview of the industry including definitions, ...
(Date:7/11/2014)... Australia , July 11, 2014  Australian drug ... announced that it has raised A$19.3 million via a ... Europe , the U.S., Asia ... A$3 million from a share purchase plan (SPP) to ... million will be made in two tranches. ...
(Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2
... Dec. 17 Novavax, Inc.,(Nasdaq: NVAX ) ... recombinant trivalent seasonal influenza virus-like particle (VLP),vaccine. The ... two,influenza vaccine programs that Novavax is developing using ... candidate is,currently in Phase I/IIa clinical trials., ...
... Product Developed Through Joint Venture Between Bristol-Myers Squibb and ... First of Its Kind in HIV Treatment -, ... The European Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz ... ATRIPLA for commercialization in the,27 countries of the European ...
Cached Medicine Technology:Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 2Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview with Dr. ... Paddock tackles topics including main men's health concerns, ... than men, and testosterone replacement therapy, among others. In ... on Doylestown Hospital’s website, Dr. Brad Paddock says, “A ... you notice pain, bulging, or asymmetry in your lower ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Praeclarus ... Made Simple as a valuable new resource for women ... two-thirds of American women work away from their children. ... touting the benefits of breastfeeding, but often feel unsupported ... nurse their babies. With its evidence-based insights, and written ...
(Date:7/12/2014)... Augusta, GA (PRWEB) July 12, 2014 ... Nova Medical Centers, is pleased to announce that it ... , This new facility will join four Atlanta-based ... will be located at 3209 Deans Bridge Road, and ... Monday through Friday. , “With Nova’s treatment philosophy ...
(Date:7/11/2014)... July 12, 2014 According to ... total market is expected to register a CAGR ... , Browse 71 market data tables and 76 ... on "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early ... http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides market ...
(Date:7/11/2014)... 2014 (HealthDay News) -- People with the lowest incomes may ... artery disease (PAD), a new study suggests. People with ... the limbs, most often the legs. The condition causes leg ... arteries throughout the body. People with PAD have a higher ... from nearly 6,800 people with PAD who took part in ...
Breaking Medicine News(10 mins):Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Poor More Prone to Leg Circulation Trouble 2
... the 1960s, surgeons experimented by transplanting chimpanzee organs into humans ... received a baboon heart and survived 20 days. // Since ... source for organs, tissues and cells to treat various diseases, ... the controversy surrounding cross-species transplant -- also known as xenotransplantation. ...
... diabetes is important because lifestyle changes and medication can prevent ... glucose tolerance test is used to identify high-risk individuals for ... study finds a cluster of risk //factors known as metabolic ... other risk factors. ,Metabolic syndrome has been shown ...
... osteoarthritis and rheumatoid arthritis cause joint pain and //stiffness ... no effective treatment to repair damaged cartilage. ... drug to prevent the onset of arthritis. The research ... a pivotal role in the onset of the condition. ...
... births of their first two children are more likely to deliver ... the same partner.// These babies are also ... results are the same even when researchers take into account the ... of birth. ,Researchers speculate that women who change ...
... the right mattress can make a difference. //Three-quarters of physicians ... a new study says they could be wrong. The new ... pain. ,Physicians often get frustrated when patients ask ... back pain. Few studies have been done on this issue ...
... night outlawed tobacco use in the Commonwealth's restaurants, taverns, ... on Sunday liquor-store sales as the House and Senate ... ,Working until nearly midnight, lawmakers also approved a sales ... thereby pumping up the state's flagging economy, and approved ...
Cached Medicine News:Health News:Animals Can give us a second chance at life 2Health News:Predictors for Type 2 Diabetes 2Health News:Changing Partners may put Expectant Mothers at Risk 2Health News:Senate assures ban on smoking 2Health News:Senate assures ban on smoking 3Health News:Senate assures ban on smoking 4
... world-class clinician documentation and electronic medical record ... the specific needs of intensive care units ... deep clinical functionality has secured its place ... in critical care, and its the most ...
... EncounterPRO Electronic Health Record ... System (WfMS) Specialties that ... and Immunology, Cardiology, Dermatology, ... Medicine, Neurology, Neurosurgery, Obstetrics ...
... developed a touchscreen EHR and is scheduled ... user can choose to use a mouse, ... eye contact while recording encounter results. If ... also runs on a pen tablet that ...
Dairylands Health Information Management solutions provides healthcare organizations a suite of integrated applications for managing patient records, optimizing reimbursement and regulatory complianc...
Medicine Products: